Eversheds Sutherland has advised Edwards Lifesciences on the USD 4.2 billion sale of its Critical Care product group to Becton, Dickinson, and Company. Baker McKenzie reportedly advised Becton, Dickinson, and Company.
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. The Critical Care product group operates in advanced patient monitoring with advanced AI algorithms serving millions of patients globally.
Becton, Dickinson, and Company is a medical technology company.
The Eversheds Sutherland team included Czech Republic-based Partner Jaroslav Tajbr and further team members in the UK.
Editor's Note: After this article was published, Kyriakides Georgopoulos announced that it advised Becton, Dickinson, and Company as well.
